請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/91657完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 郭彥彬 | zh_TW |
| dc.contributor.advisor | Yen-Ping Kuo | en |
| dc.contributor.author | 詹世華 | zh_TW |
| dc.contributor.author | Shi-Hua Zhan | en |
| dc.date.accessioned | 2024-02-20T16:25:05Z | - |
| dc.date.available | 2024-02-21 | - |
| dc.date.copyright | 2024-02-20 | - |
| dc.date.issued | 2023 | - |
| dc.date.submitted | 2023-11-28 | - |
| dc.identifier.citation | 1. Abati, S., Bramati, C., Bondi, S., Lissoni, A., & Trimarchi, M. (2020). Oral cancer and precancer: a narrative review on the relevance of early diagnosis. International Journal of Environmental Research and Public Health, 17(24), 9160.
2. Montero, P. H., & Patel, S. G. (2015). Cancer of the oral cavity. Surgical Oncology Clinics, 24(3), 491-508. 3. Su, S. Y. (2022). Evaluation of Nationwide Oral Mucosal Screening Program for Oral Cancer Mortality among Men in Taiwan. International Journal of Environmental Research and Public Health, 19(21), 14329. 4. Huang, C. C., Lin, C. N., Chung, C. H., Hwang, J. S., Tsai, S. T., & Wang, J. D. (2019). Cost-effectiveness analysis of the oral cancer screening program in Taiwan. Oral Oncology, 89, 59-65. 5. Warnakulasuriya, S., & Chen, T. H. H. (2022). Areca nut and oral cancer: Evidence from studies conducted in humans. Journal of Dental Research, 101(10), 1139-1146. 6. D’souza, S., & Addepalli, V. (2018). Preventive measures in oral cancer: An overview. Biomedicine & Pharmacotherapy, 107, 72-80. 7. Nair, D. R., Pruthy, R., Pawar, U., & Chaturvedi, P. (2012). Oral cancer: Premalignant conditions and screening-an update. Journal of Cancer Research and Therapeutics, 8(Suppl 2), S57-S66. 8. Rhodus, N. L., Kerr, A. R., & Patel, K. (2014). Oral cancer: Leukoplakia, premalignancy, and squamous cell carcinoma. Dental Clinics, 58(2), 315-340. 9. Tirelli, G., Gatto, A., Nata, F. B., Bussani, R., Piccinato, A., Marcuzzo, A. V., & Tofanelli, M. (2018). Prognosis of oral cancer: A comparison of the staging systems given in the 7th and 8th editions of the American Joint Committee on Cancer Staging Manual. British Journal of Oral and Maxillofacial Surgery, 56(1), 8-13. 10. Valdez, J. A., & Brennan, M. T. (2018). Impact of oral cancer on quality of life. Dental Clinics, 62(1), 143-154. 11. Omura, K. (2014). Current status of oral cancer treatment strategies: Surgical treatments for oral squamous cell carcinoma. International Journal of Clinical Oncology, 19, 423-430. 12. Rodini, C. O., Lopes, N. M., Lara, V. S., & Mackenzie, I. C. (2017). Oral cancer stem cells-properties and consequences. Journal of Applied Oral Science, 25, 708-715. 13. Liu, Y., Yang, M., Luo, J., & Zhou, H. (2020). Radiotherapy targeting cancer stem cells "awakens" them to induce tumour relapse and metastasis in oral cancer. International Journal of Oral Science, 12(1), 19. 14. Warnakulasuriya, S., & Chen, T. H. H. (2022). Areca nut and oral cancer: Evidence from studies conducted in humans. Journal of Dental Research, 101(10), 1139-1146. 15. Liu, Y. J., Peng, W., Hu, M. B., Xu, M., & Wu, C. J. (2016). The pharmacology, toxicology and potential applications of Arecoline: A review. Pharmaceutical Biology, 54(11), 2753-2760. 16. Fox, A. H., Lam, Y. W., Leung, A. K., Lyon, C. E., Andersen, J., Mann, M., & Lamond, A. I. (2002). Paraspeckles: A novel nuclear domain. Current Biology, 12(1), 13-25. 17. Yeh, H. W., Hsu, E. C., Lee, S. S., Lang, Y. D., Lin, Y. C., Chang, C. Y., ... & Jou, Y. S. (2018). PSPC1 mediates TGF-β1 autocrine signalling and Smad2/3 target switching to promote EMT, stemness and metastasis. Nature Cell Biology, 20(4), 479-491. 18. Bond, C. S., & Fox, A. H. (2009). Paraspeckles: Nuclear bodies built on long noncoding RNA. Journal of Cell Biology, 186(5), 637-644. 19. Gao, X., Kong, L., Lu, X., Zhang, G., Chi, L., Jiang, Y., ... & Yang, J. (2014). Paraspeckle protein 1 (PSPC1) is involved in the cisplatin-induced DNA damage response—Role in G1/S checkpoint. PloS One, 9(5), e97174. 20. Maiese, K., Holloway, H. H., Larson, D. M., & Soncrant, T. T. (1994). Effect of acute and chronic Arecoline treatment on cerebral metabolism and blood flow in the conscious rat. Brain Research, 641(1), 65-75. 21. Sullivan, R. J., Allen, J. S., Otto, C., Tiobech, J., & Nero, K. (2000). Effects of chewing betel nut (Areca catechu) on the symptoms of people with schizophrenia in Palau, Micronesia. The British Journal of Psychiatry, 177(2), 174-178. 22. Ling, H. Y., Wang, G., Zhang, W., Li, X., Zhou, S. H., & Hu, B. (2012). Arecoline improves vascular endothelial function in high fructose-fed rats via increasing cystathionine-γ-lyase expression and activating KATP channels. Acta Pharmacologica Sinica, 33(8), 1023-1029. 23. Chen, D., Mu, S., & Wang, H. (1986). Antithrombosis through activating endothelial target for acetylcholine and its molecular mechanism. Chinese Pharmacological Bulletin. 24. Calogero, A. E., Kamilaris, T. C., Gomez, M. T., Johnson, E. O., Tartaglia, M. E., Gold, P. W., & Chrousos, G. P. (1989). The muscarinic cholinergic agonist Arecoline stimulates the rat hypothalamic-pituitary-adrenal axis through a centrally-mediated corticotropin-releasing hormone-dependent mechanism. Endocrinology, 125(5), 2445-2453. 25. Dasgupta, R., Chatterji, U., Nag, T. C., Chaudhuri-Sengupta, S., Nag, D., & Maiti, B. R. (2010). Ultrastructural and hormonal modulations of the thyroid gland following Arecoline treatment in albino mice. Molecular and Cellular Endocrinology, 319(1-2), 1-7. 26. Si, C. F., Wei, M. X., & Kyoshi, N. (2004). A study of the effects of arecaline hydrobromide on the dispersed colonic smooth muscle cells in rats. Shanghai Journal of Traditional Chinese Medicine, 38, 48-50. 27. Zhao, W. A., Li, Z. M., & Wang, B. X. (2003). Morphological observation of semen areca and white pepper against cysticercus cellulosae in vitro. Modern Journal of Integrated Chinese Traditional and Western Medicine, 12(3), 237-238. 28. Ji, W. T., Yang, S. R., Chen, J. Y. F., Cheng, Y. P., Lee, Y. R., Chiang, M. K., & Chen, H. R. (2012). Arecoline downregulates levels of p21 and p27 through the reactive oxygen species/mTOR complex 1 pathway and may contribute to oral squamous cell carcinoma. Cancer Science, 103(7), 1221-1229. 29. Lee, S. S., Tsai, C. H., Tsai, L. L., Chou, M. C., Chou, M. Y., & Chang, Y. C. (2012). β-catenin expression in areca quid chewing-associated oral squamous cell carcinomas and upregulated by Arecoline in human oral epithelial cells. Journal of the Formosan Medical Association, 111(4), 194-200. 30. Khan, I., Kumar, N., Pant, I., Narra, S., & Kondaiah, P. (2012). Activation of TGF-β pathway by areca nut constituents: a possible cause of oral submucous fibrosis. PloS One, 7(12), e51806. 31. Li, J., Chen, S., Liao, Y., Wang, H., Zhou, D., & Zhang, B. (2022). Arecoline is associated with inhibition of cuproptosis and proliferation of cancer-associated fibroblasts in oral squamous cell carcinoma: a potential mechanism for tumor metastasis. Frontiers in Oncology, 12, 925743. 32. Mohankumar, K., Shrestha, R., & Safe, S. (2022). Nuclear receptor 4A1 (NR4A1) antagonists target paraspeckle component 1 (PSPC1) in cancer cells. Molecular Carcinogenesis, 61(1), 73-84. 33. Chang, M. C., Ho, Y. S., Lee, P. H., Chan, C. P., Lee, J. J., Hahn, L. J., ... & Jeng, J. H. (2001). Areca nut extract and Arecoline induced the cell cycle arrest but not apoptosis of cultured oral KB epithelial cells: association of glutathione, reactive oxygen species and mitochondrial membrane potential. Carcinogenesis, 22(9), 1527-1535. 34. Haque, M. F., Meghji, S., Khitab, U., & Harris, M. (2000). Oral submucous fibrosis patients have altered levels of cytokine production. Journal of oral pathology & medicine, 29(3), 123-128. 35. Arakeri, G., & Brennan, P. A. (2013). Oral submucous fibrosis: an overview of the aetiology, pathogenesis, classification, and principles of management. British Journal of Oral and Maxillofacial Surgery, 51(7), 587-593. 36. Chang, Y. C., Tsai, C. H., Lai, Y. L., Yu, C. C., Chi, W. Y., Li, J. J., & Chang, W. W. (2014). Arecoline‐induced myofibroblast transdifferentiation from human buccal mucosal fibroblasts is mediated by ZEB 1. Journal of cellular and molecular medicine, 18(4), 698-708. 37. Guha, N., Warnakulasuriya, S., Vlaanderen, J., & Straif, K. (2014). Betel quid chewing and the risk of oral and oropharyngeal cancers: a meta‐analysis with implications for cancer control. International journal of cancer, 135(6), 1433-1443. 38. Pant, I., Rao, S. G., & Kondaiah, P. (2016). Role of areca nut induced JNK/ATF2/Jun axis in the activation of TGF-β pathway in precancerous Oral Submucous Fibrosis. Scientific reports, 6(1), 34314. 39. Peng, D., Fu, M., Wang, M., Wei, Y., & Wei, X. (2022). Targeting TGF-β signal transduction for fibrosis and cancer therapy. Molecular cancer, 21(1), 104. 40. Ren, H., He, G., Lu, Z., He, Q., Li, S., Huang, Z., ... & Wang, A. (2021). Retracted: Arecoline induces epithelial‐mesenchymal transformation and promotes metastasis of oral cancer by SAA1 expression. Cancer science, 112(6), 2173-2184. 41. Wang, T. Y., Peng, C. Y., Lee, S. S., Chou, M. Y., Yu, C. C., & Chang, Y. C. (2016). Acquisition cancer Stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to Arecoline. Oncotarget, 7(51), 84072. 42. Chen, Y. L., Liu, K. J., Jang, C. W., Hsu, C. C., Yen, Y. C., Liu, Y. L., ... & Chen, Y. W. (2019). ERK activation modulates cancer Stemness and motility of a novel mouse oral squamous cell carcinoma cell line. Cancers, 12(1), 61. 43. Morikawa, M., Derynck, R., & Miyazono, K. (2016). TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology. Cold Spring Harbor perspectives in biology, 8(5), a021873. 44. Lodyga, M., & Hinz, B. (2020, May). TGF-β1–a truly transforming growth factor in fibrosis and immunity. Seminars in cell & developmental biology, 101, 123-139. 45. Montague, T. G., & Schier, A. F. (2017). Vg1-Nodal heterodimers are the endogenous inducers of mesendoderm. Elife, 6, e28183. 46. Lyon, M., Rushton, G., & Gallagher, J. T. (1997). The interaction of the transforming growth factor-βs with heparin/heparan sulfate is isoform-specific. Journal of Biological Chemistry, 272(29), 18000-18006. 47. Groeneveldt, C., van Hall, T., van der Burg, S. H., Ten Dijke, P., & van Montfoort, N. (2020). Immunotherapeutic potential of TGF-β inhibition and oncolytic viruses. Trends in immunology, 41(5), 406-420. 48. Katsuno, Y., Lamouille, S., & Derynck, R. (2013). TGF-β signaling and epithelial–mesenchymal transition in cancer progression. Current opinion in oncology, 25(1), 76-84. 49. Iwano, M. (2010). EMT and TGF-beta in renal fibrosis. Front Biosci (Schol Ed), 2(1), 229-238. 50. Batlle, E., & Massagué, J. (2019). Transforming growth factor-β signaling in immunity and cancer. Immunity, 50(4), 924-940. 51. Groppe, J., Hinck, C. S., Samavarchi-Tehrani, P., Zubieta, C., Schuermann, J. P., Taylor, A. B., ... & Hinck, A. P. (2008). Cooperative assembly of TGF-β superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Molecular cell, 29(2), 157-168. 52. Xiao, Z., Watson, N., Rodriguez, C., & Lodish, H. F. (2001). Nucleocytoplasmic shuttling of Smad1 conferred by its nuclear localization and nuclear export signals. Journal of Biological Chemistry, 276(42), 39404-39410. 53. Wang, G., Long, J., Matsuura, I., He, D., & Liu, F. (2005). The Smad3 linker region contains a transcriptional activation domain. Biochemical Journal, 386(1), 29-34. 54. Hanyu, A., Ishidou, Y., Ebisawa, T., Shimanuki, T., Imamura, T., & Miyazono, K. (2001). The N domain of Smad7 is essential for specific inhibition of transforming growth factor-β signaling. The Journal of cell biology, 155(6), 1017-1028. 55. Zhang, Y. E. (2017). Non-Smad signaling pathways of the TGF-β family. Cold Spring Harbor perspectives in biology, 9(2), a022129. 56. Shen, W., Tao, G. Q., Zhang, Y., Cai, B., Sun, J., & Tian, Z. Q. (2017). TGF-β in pancreatic cancer initiation and progression: two sides of the same coin. Cell & bioscience, 7, 1-7. 57. Akhurst, R. J., & Derynck, R. (2001). TGF-β signaling in cancer–a double-edged sword. Trends in cell biology, 11(11), S44-S51. 58. Xu, J., Lamouille, S., & Derynck, R. (2009). TGF-β-induced epithelial to mesenchymal transition. Cell research, 19(2), 156-172. 59. Moustakas, A., & Heldin, C. H. (2012, October). Induction of epithelial–mesenchymal transition by transforming growth factor β. In Seminars in cancer biology, 22(5-6), 446-454. 60. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences, 100(7), 3983-3988. 61. Scheel, C., & Weinberg, R. A. (2011). Phenotypic plasticity and epithelial‐mesenchymal transitions in cancer and normal stem cells? International journal of cancer, 129(10), 2310-2314. 62. Jen, H. W., Gu, D. L., Lang, Y. D., & Jou, Y. S. (2020). PSPC1 Potentiates IGF1R expression to augment cell adhesion and motility. Cells, 9(6), 1490. 63. Shao, W., Bi, X., Pan, Y., Gao, B., Wu, J., Yin, Y., ... & Shen, X. (2022). Phase separation of RNA-binding protein promotes polymerase binding and transcription. Nature Chemical Biology, 18(1), 70-80. 64. Lang, Y. D., Chen, H. Y., Ho, C. M., Shih, J. H., Hsu, E. C., Shen, R., ... & Jou, Y. S. (2019). PSPC1-interchanged interactions with PTK6 and β-catenin synergize oncogenic subcellular translocations and tumor progression. Nature Communications, 10(1), 5716. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/91657 | - |
| dc.description.abstract | 根據111年衛生福利部公佈的十大癌症死因死亡率統計，口腔癌高居男性十大癌症死亡率的第四位。抽菸、喝酒與嚼檳榔，為台灣口腔癌的主要致病危險因子。嚼檳榔危險因子比起抽菸更具統計意義。近年來發現癌幹細胞是癌症轉移和復發的主要原因。實驗室先前以微陣列分析口腔癌SAS細胞株及具有幹細胞特性的SAS聚球體細胞基因表現圖譜差異，合併比較檳榔鹼Arecoline處理SAS細胞後的表現差異，找出交集基因，篩選出PSPC1 (Paraspeckle component 1)。 PSPC1曾被報告能促進肺癌細胞上皮細胞間質轉化(EMT)、癌幹細胞特性表現，並活化 TGF-β，促進癌細胞轉移。實驗室先前發現PSPC1在口腔癌組織有過度表現。但在口腔癌致癌的角色及機轉並不清楚。為瞭解 PSPC1在口腔癌的角色及機轉。我們首先以Arecoline處理人類口腔上皮SG細胞，發現Arecoline可增加SG細胞PSPC1的表現量。加入TGF-β中和抗體、ALK5抑制劑、Smad3抑制劑，可抑制Arecoline誘導的PSPC1表現。顯示 Arecoline經由TGF-β刺激PSPC1的表現。前處理MEK、JNK、P38和PI3K抑制劑，可降低TGF-β刺激SG細胞株和TW2.6口腔癌細胞株PSPC1的表現。顯示TGF-β會透過SMAD及NON SMAD路徑來誘導PSPC1表現。我們進一步將PSPC1 cDNA 轉染至 PSPC1表現量較低的TW2.6細胞，發現可增強其細胞爬行和侵襲的能力，EMT 和 Stemness相關蛋白表現和形成聚球體的能力。使用PSPC1 siRNA knockdown PSPC1表現量較多的SAS和FaDu聚球體細胞。結果發現可降低聚球體細胞爬行和侵襲的能力，EMT相關蛋白和 Stemness相關蛋白表現和形成聚球體的能力。 | zh_TW |
| dc.description.abstract | The chewing of areca nut (AN, Areca catechu) preparations has been associated with the high incidence of oral cancer observed in Taiwan. However, the mechanisms are still not completely clear. Paraspeckles compound 1 (PSPC1) is a multifunctional protein that has been shown to promote tumorigenesis, epithelial-to-mesenchymal transition (EMT), stemness and metastasis in multiple cell types. Our preliminary study showed PSPC1 is overexpressed in oral cancer. This study showed Arecoline, a main alkaloid of areca nut, induced the expression of PSPC1 protein in oral epithelial SG cell line. Pretreatment with TGF-β neutralizing antibody, SB431542 and smad3 inhibitor SIS3 inhibit the Arecoline-induced PSPC1 expression, indicating Arecoline-induced PSPC1 expression is mediated by TGF-β1. Pretreatment with inhibitors of MEK, JNK, P38, and PI3K, reduced TGF-β1-induced PSPC1 expression. Human buccal SCC TW2.6 cells with PSPC1 overexpression exhibited enhanced migration, invasion, epithelial–mesenchymal transition (EMT), cancer stem cell (CSC) phenotypes. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2024-02-20T16:25:05Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2024-02-20T16:25:05Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 誌謝 i
口試委員會審定書 ii 中文摘要 iii Abstract iv 目 次 v 一、研究背景與文獻回顧 1 1.1口腔癌 1 1.2檳榔鹼 3 1.3 Paraspeckle Component 1 ( PSPC1 ) 4 1.4 乙型轉化生長因子Transforming growth factor-β1 (TGF-β1) 6 二、研究動機與目的 8 三、材料與方法 9 2.1細胞培養 9 2.2細胞冷凍 9 2.3藥物處理 9 2.4西方墨點法 10 2.5 細胞增生速率測試 (Cell proliferation assay) 13 2.6細胞存活率試驗 (MTT assay) 13 2.7細胞移動性實驗 (Migration assay) 13 2.8細胞侵襲性試驗 (Invasion assay) 14 2.9細胞聚球體形成試驗 (Sphere forming assay) 14 2.10細胞聚球體 PSPC1基因Knockdown實驗 15 2.11抽取質體並建立PSPC1過表達的TW2.6細胞 15 2.12活體小鼠實驗 16 四、實驗結果 17 4.1觀察各口腔癌細胞中PSPC1的表現 17 4.2檳榔鹼Arecoline誘導SG細胞中的PSPC1表現量上升 17 4.3檳榔鹼Arecoline透過TGF-β訊號傳遞路徑誘導PSPC1的表現 17 4.4 TGF-β誘導SG和TW2.6細胞中的PSPC1表現上升 18 4.5 TGF-β亦透過non-Smad訊息傳遞路徑影響PSPC1表現 18 4.6 PSPC1的過表現會促進TW2.6細胞migration和invasion的能力 18 4.7 PSPC1過表現會促進TW2.6細胞的EMT markers表現 19 4.8 PSPC1過表達會促進TW2.6細胞的Stemness markers表現 19 4.9 PSPC1過表現能增強TW2.6細胞形成spheres的能力 19 4.11 降低PSPC1 的表現會減少FaDu sphere細胞migration和invasion能力 20 4.12降低PSPC1 的表現會減少FaDu SP和SAS SP細胞EMT markers表現 20 4.13降低PSPC1 的表達會減少FaDu SP和SAS SP細胞Stemness markers表現 21 4.14降低PSPC1 的表達會減少FaDu SP和SAS SP細胞 Sphere forming的能力 21 4.15 PSPC1的過表現會增加TW2.6細胞的生長速度 22 4.16 PSPC1的過表現能夠增加腫瘤在小鼠體內的發生 22 4.17 PSPC1的過表現能夠增加腫瘤在小鼠體內的生長 23 五、討論 24 六、圖與表 27 圖一、各口腔癌細胞株的內生性PSPC1蛋白質表現量 27 圖二、檳榔鹼誘導SG細胞中的PSPC1蛋白質表現上升 28 圖三、檳榔鹼透過TGF-β訊息傳遞路徑誘導PSPC1的蛋白質表現量 29 圖四、TGF-β誘導SG和TW2.6細胞中的PSPC1的蛋白質表現量上升 30 圖五、TGF-β誘導SG和TW2.6細胞中的PSPC1的蛋白質表現量上升 31 圖六、TGF-β透過non-Smad訊息傳遞路徑誘導PSPC1的蛋白質表現量 32 圖七、PSPC1的過表達影響TW2.6細胞migration能力 33 圖八、PSPC1的過表達影響TW2.6細胞invasion能力 34 圖九、PSPC1的過表達對TW2.6細胞EMT markers的影響 35 圖十、PSPC1的過表達對TW2.6細胞stemness markers的影響 36 圖十一、PSPC1的過表達影響TW2.6細胞形成spheres能力 37 圖十二、Spheres型態的FaDu和SAS細胞PSPC1表現較高 38 圖十三、降低PSPC1的表達影響FaDu SP細胞migration能力 39 圖十四、降低PSPC1的表達影響FaDu SP細胞invasion能力 40 圖十五、降低PSPC1的表達對FaDu SP細胞EMT markers的影響 41 圖十六、降低PSPC1的表達對SAS SP細胞EMT markers的影響 42 圖十七、降低PSPC1的表達對FaDu SP細胞stemness markers的影響 43 圖十八、降低PSPC1的表達對SAS SP細胞stemness markers的影響 44 圖十九、降低PSPC1的表達影響FaDu SP細胞形成spheres能力 45 圖二十、降低PSPC1的表達影響SAS SP細胞形成spheres能力 46 圖二十一、PSPC1的過表達 會影響TW2.6細胞的生長 47 圖二十二、PSPC1的過表達能夠增加腫瘤在小鼠體內的發生 48 圖二十三、PSPC1的過表達能夠增加腫瘤在小鼠體內的生長 49 參考文獻 50 | - |
| dc.language.iso | zh_TW | - |
| dc.title | 旁斑蛋白組成成分1 (PSPC1) 誘導口腔癌細胞EMT與幹細胞特性之研究 | zh_TW |
| dc.title | PSPC1 induced epithelial mesenchymal transition and stemness in oral cancer | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 112-1 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.coadvisor | 鄭世榮 | zh_TW |
| dc.contributor.coadvisor | Shih-Jung Cheng | en |
| dc.contributor.oralexamcommittee | 張國威 | zh_TW |
| dc.contributor.oralexamcommittee | Kuo-Wei Chang | en |
| dc.subject.keyword | 口腔癌, | zh_TW |
| dc.subject.keyword | Oral cancer,PSPC1,EMT,Stemness, | en |
| dc.relation.page | 58 | - |
| dc.identifier.doi | 10.6342/NTU202304456 | - |
| dc.rights.note | 未授權 | - |
| dc.date.accepted | 2023-11-30 | - |
| dc.contributor.author-college | 醫學院 | - |
| dc.contributor.author-dept | 口腔生物科學研究所 | - |
| 顯示於系所單位： | 口腔生物科學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-112-1.pdf 目前未授權公開取用 | 3.89 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。